Invion lands US$16.2M facility to cover most of its trial costs
What's the deal? Australian biotech InvionDealroom has a profile for this one. Try Dealroom → has secured two financing arrangements expected to cover up to about 85% of its current and future clinical trial costs. The centrepiece is a binding Co-Funding and Option Deed with Point8 Capital, a multi-year facility of up to US$16.2M.
How it works: Point8 will co-fund 50% of clinical trial invoices in return for options over 10% of Invion's share capital. Those options vest only if funding is provided and a candidate reaches Phase 3, subject to shareholder approval — tying Point8's upside to Invion's trial progress.
What else is in the structure? A separate secured loan from Rockford RDF, via Rockford CapitalDealroom has a profile for this one. Try Dealroom →, provides an R&D tax incentive financing facility of up to US$4.85M across FY27 and FY28. It carries a 16% interest rate and first-ranking security over Invion's research and development tax receivables, advancing refundable offsets ahead of tax refunds.
What's the endgame? The money is designed to release as clinical research organisation invoices fall due, easing cash flow as Invion advances its non-melanoma skin cancer and upcoming anogenital cancer programmes. It builds on partner-funded work, including up to US$1.29M from Hanlim and South Korea's KDDFDealroom has a profile for this one. Try Dealroom → for preclinical oesophageal-cancer research.
What could go wrong? The headline figure is not US$21M of unrestricted cash. Coverage depends on the facilities' terms and eligible trial spending, so the practical value hinges on how dependably the arrangements fund trials.
The signal: For a small biotech that has leaned on shareholder-backed convertible notes and tax-rebate advances, the structure matters as much as the sum. By linking financing to invoices and clinical milestones, Invion is trying to fund late-stage trials while limiting further dilution.
Read more: tipranks.com
Image credit: Generated with Gemini
